Clinical Trials Sponsored by Mirati Therapeutics Inc.

Total 3029 results

Mirati Therapeutics Inc.

Completed

A PK Study to Assess the Drug-drug Interaction of a BCRP Inhibitor on Adagrasib

Healthy Adults

United States
Mirati Therapeutics Inc.

Active, not recruiting

Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies

Clear-Cell Renal Cell Carcinoma

United States
Mirati Therapeutics Inc.

Completed

PK Study to Assess Drug-drug Interaction and QTc Between Sitravatinib and a Cocktail of Substrates

Advanced Solid Tumor

United States
Mirati Therapeutics Inc.

Completed

PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.

Healthy Adults

United States
Mirati Therapeutics Inc.

Completed

Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer

Advanced Cancer

Korea, Republic of, United States
Mirati Therapeutics Inc.

Enrolling by invitation

Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study

Advanced or Metastatic Solid Malignancies

United States
Mirati Therapeutics Inc.

Active, not recruiting

Adagrasib in Combination With Palbociclib in Patients With Advanced Solid Tumors (KRYSTAL-16)

Advanced Solid Tumor

United States
Mirati Therapeutics Inc.

Completed

A Study to Explore the Effect of Food Before a Single Dose of Sitravatinib

Healthy Adults

United States
Mirati Therapeutics Inc.

Terminated

Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC

Advanced Cancer

United States
Mirati Therapeutics Inc.

Completed

Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies

Advanced Cancer

United States, Korea, Republic of, Canada
Mirati Therapeutics Inc.

Completed

Safety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDS

Myelodysplastic Syndrome

United States
Mirati Therapeutics Inc.

Completed

Study of Mocetinostat in Patients With Urothelial Carcinoma Having Inactivating Alterations of Specific Genes

Urothelial Carcinoma

United States
Mirati Therapeutics Inc.

Completed

A Phase I/II Study of MGCD0103 With Azacitidine in Patients With High-Risk Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Mirati Therapeutics Inc.

Terminated

A Study of MGCD265 Given With Erlotinib or Docetaxel in Subjects With Advanced Malignancies or Non-Small Cell Lung Cancer

Advanced Malignancies, Non-small Cell Lung Cancer

United States
Mirati Therapeutics Inc.

Completed

A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

United States, Canada
Mirati Therapeutics Inc.

Completed

Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Non Hodgkin's Lymphoma | Tumors

Canada, United States
Mirati Therapeutics Inc.

Completed

Safety Study of Two Oral Formulations of MGCD265 Administered in Healthy Subjects in the Fasting State

Advanced Malignancies

United States
Mirati Therapeutics Inc.

Recruiting

Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation (202200050434)

Metastatic Lung Cancer | Advanced NSCLC

United States, Spain, Greece, Hungary, France, Italy, Poland
Mirati Therapeutics Inc.

Recruiting

Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion

Pancreatic Adenocarcinoma | Solid Tumor | Non Small Cell Lung Cancer | Mesothelioma | Advanced Solid Tumor | Malignant Peripheral Nerve Sheath Tumors

United States
Mirati Therapeutics Inc.

Terminated

Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States
Mirati Therapeutics Inc.

Active, not recruiting

Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-12)

Advanced Non Small Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer

United States, Australia, France, Italy, Korea, Republic of, Poland, Russian Federation, Spain, United Kingdom, China, Romania, Netherlands, Hong Kong, Austria, Belgium, Czechia, Hungary, Portugal, Greece, Germany, Ireland, Switze... and more
Mirati Therapeutics Inc.

Active, not recruiting

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

Metastatic Colorectal Cancer | Advanced Colorectal Cancer

United States, Denmark, Finland, Italy, Spain, Belgium, Romania, Taiwan, Thailand, France, Germany, Korea, Republic of, China, Malaysia, Hong Kong, Australia, Austria, Puerto Rico, Singapore, Canada, Portugal, Poland, Greece, United Kingdom and more
Mirati Therapeutics Inc.

Completed

A PK Study to Assess the Drug-drug Interaction of a Strong CYP2C8 Inhibitor on Adagrasib

Healthy Adults

United States
Mirati Therapeutics Inc.

Completed

A Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Sitravatinib

Hepatic Impairment

United States
Mirati Therapeutics Inc.

Approved for marketing

Expanded Access of Adagrasib (MRTX849) in Patients With Advanced Solid Tumors Who Have a KRAS G12C Mutation

Metastatic Cancer | Advanced Cancer | Malignant Neoplasm

United States
Mirati Therapeutics Inc.

Completed

Phase 2 Study of MGCD265 in Patients With Non-Small Cell Lung Cancer With Activating Genetic Alterations in MET

Non-Small Cell Lung Cancer

United States, Korea, Republic of, Hungary, United Kingdom, Italy, Australia, Taiwan, Poland, Canada
Mirati Therapeutics Inc.

Terminated

Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Hodgkin's Lymphoma

United States, Canada
Mirati Therapeutics Inc.

Completed

A Phase II Study of MGCD0103 (MG-0103) in Patients With Refractory Chronic Lymphocytic Leukemia

Lymphocytic Leukemia, Chronic

United States, Canada
Mirati Therapeutics Inc.

Completed

Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma

Lymphoma

United States, Canada
Mirati Therapeutics Inc.

Terminated

Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndrome (MDS)

United States, Canada, United Kingdom
Mirati Therapeutics Inc.

Terminated

Study to Evaluate Combination Treatment of MGCD0103 and Docetaxel (Taxotere®) for Subjects With Advanced Cancer Tumors

Stomach Cancer | Breast Cancer | Gastric Cancer | Lung Cancer | Prostate Cancer | Non-Small-Cell Lung Carcinoma | Prostatic Cancer | Pulmonary Cancer

United States
Mirati Therapeutics Inc.

Recruiting

Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)

Metastatic Cancer | Advanced Cancer | Malignant Neoplasm of Lung

Korea, Republic of, United States, Turkey, France, Taiwan
Mirati Therapeutics Inc.

Recruiting

Study of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation

Pancreatic Adenocarcinoma | Solid Tumor | Advanced Solid Tumor | Non-small Cell Lung Cancer | Colo-rectal Cancer

United States
Mirati Therapeutics Inc.

Recruiting

A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

Solid Tumor | Non Small Cell Lung Cancer | Advanced Solid Tumor | Colo-rectal Cancer

United States, Puerto Rico
Mirati Therapeutics Inc.

Recruiting

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Advanced Non-Small Cell Lung Cancer | Metastatic Non-Small Cell Lung Cancer

United States, Korea, Republic of, Italy, Spain, Czechia, Hungary, Netherlands, Canada, Australia, Austria, Belgium, Germany, Ireland, Israel, Poland, United Kingdom, Taiwan, Portugal
Mirati Therapeutics Inc.

Recruiting

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Metastatic Cancer | Advanced Cancer | Malignant Neoplastic Disease

United States, Puerto Rico
Mirati Therapeutics Inc.

Completed

Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma

Clear Cell Renal Cell Carcinoma

United States
Mirati Therapeutics Inc.

Terminated

A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma

Urothelial Carcinoma Bladder | Urothelial Carcinoma | Urothelial Carcinoma Ureter | Urothelial Carcinoma of the Renal Pelvis and Ureter | Urothelial Carcinoma Urethra

United States
Mirati Therapeutics Inc.

Completed

A Study to Explore the Effect of Acid-reducing Agents

Healthy Adults

United States
Mirati Therapeutics Inc.

Terminated

MGCD0103 Administered in Combination With Azacitidine (Vidaza®) to Subjects With Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma

Hodgkin Lymphoma | Non-Hodgkin Lymphoma (Follicular or Large Diffuse B-cell Lymphoma or Mantle Cell Lymphoma)

United States
Mirati Therapeutics Inc.

Completed

A Phase I/II Study of MGCD0103 (MG-0103) in Combination With Gemcitabine

Tumors

United States, Canada
Mirati Therapeutics Inc.

Terminated

MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With Relapsed/Refractory Disease

Myelodysplastic Syndromes | Myelogenous Leukemia, Acute

United States, Canada
Mirati Therapeutics Inc.

Completed

Single Dose Comparative Bioavailability Study Of MGCD265 In Healthy Male And Female Volunteers

Healthy

Canada
Mirati Therapeutics Inc.

Completed

Safety Study of Oral MGCD265 Administered With Interruption to Subjects With Advanced Malignancies

Advanced Malignancies

United States
Mirati Therapeutics Inc.

Completed

A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

Canada, United States
Mirati Therapeutics Inc.
Novartis

Active, not recruiting

Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)

Metastatic Cancer | Advanced Cancer | Malignant Neoplastic Disease

United States
Verastem, Inc.
Mirati Therapeutics Inc.

Recruiting

Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients (RAMP204)

Non Small Cell Lung Cancer | Metastatic Cancer | Advanced Cancer | Malignant Neoplasm of Lung | Malignant Neoplastic Disease | KRAS Activating Mutation

United States
Mirati Therapeutics Inc.
Boehringer Ingelheim

Completed

Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)

Metastatic Cancer | Advanced Cancer | Malignant Neoplasm of Colon | Malignant Neoplasm of Lung | Malignant Neoplastic Disease

United States
Kura Oncology, Inc.
Mirati Therapeutics Inc.

Recruiting

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors (FIT-001)

Non Small Cell Lung Cancer (NSCLC) | Pancreatic Ductal Adenocarcinoma (PDAC) | Colorectal Cancer (CRC) | Clear Cell Renal Cell Carcinoma (ccRCC) | Solid Tumors With HRAS Alterations

United States
Mirati Therapeutics Inc.
Aadi Bioscience, Inc.

Recruiting

Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)

NSCLC | Metastatic Cancer | Advanced Cancer | Solid Tumor, Adult | Malignant Neoplastic Disease

United States

Clinical Trials Sponsored by Mirati Therapeutics Inc.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations